FDA — authorised 12 August 1981
- Application: NDA018485
- Marketing authorisation holder: MT ADAMS
- Local brand name: ISOPTIN
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Verapamil Injection in United States
FDA authorised Verapamil Injection on 12 August 1981 · 1 US adverse-event reports
Marketing authorisations
FDA — authorised 8 March 1982
- Application: NDA018593
- Marketing authorisation holder: MT ADAMS
- Local brand name: ISOPTIN
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 March 1984
- Application: NDA019038
- Marketing authorisation holder: GD SEARLE LLC
- Local brand name: CALAN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 10 September 1984
- Application: NDA018817
- Marketing authorisation holder: PFIZER
- Local brand name: CALAN
- Indication: TABLET — ORAL
- Status: approved
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 1
Most-reported reactions
- Product Packaging Confusion — 1 report (100%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Verapamil Injection approved in United States?
Yes. FDA authorised it on 12 August 1981; FDA authorised it on 8 March 1982; FDA authorised it on 30 March 1984.
Who is the marketing authorisation holder for Verapamil Injection in United States?
MT ADAMS holds the US marketing authorisation.